JP2008101015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008101015A5 JP2008101015A5 JP2007306088A JP2007306088A JP2008101015A5 JP 2008101015 A5 JP2008101015 A5 JP 2008101015A5 JP 2007306088 A JP2007306088 A JP 2007306088A JP 2007306088 A JP2007306088 A JP 2007306088A JP 2008101015 A5 JP2008101015 A5 JP 2008101015A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- substituents selected
- hydrocarbon ring
- membered aromatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 8
- ZPKLQDKQGVSJST-UHFFFAOYSA-N 3-methoxy-4-(4-methylimidazol-1-yl)benzaldehyde Chemical compound COC1=CC(C=O)=CC=C1N1C=C(C)N=C1 ZPKLQDKQGVSJST-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims 63
- 125000005843 halogen group Chemical group 0.000 claims 30
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 22
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 22
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 13
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 12
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 4
- -1 boronic acid ester Chemical class 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 16
- 239000002609 media Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 210000003710 Cerebral Cortex Anatomy 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 210000003754 Fetus Anatomy 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- XTIXPIMMHGCRJD-UHFFFAOYSA-N 1-(3,5-difluorophenyl)ethanamine Chemical compound CC(N)C1=CC(F)=CC(F)=C1 XTIXPIMMHGCRJD-UHFFFAOYSA-N 0.000 description 1
- OXJLDNSPGPBDCP-UHFFFAOYSA-N 1-(3,5-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC(F)=C1 OXJLDNSPGPBDCP-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- PHSPBXTVMJOTQN-UHFFFAOYSA-N COc1cc(C=O)ccc1I Chemical compound COc1cc(C=O)ccc1I PHSPBXTVMJOTQN-UHFFFAOYSA-N 0.000 description 1
- QPIPHGZNRUHSMB-IFQVXRHPSA-N C[C@@H](c1cc(F)cc(F)c1)N(CCC/C1=C\c(cc2)cc(OC)c2-[n]2cnc(C)c2)C1=O Chemical compound C[C@@H](c1cc(F)cc(F)c1)N(CCC/C1=C\c(cc2)cc(OC)c2-[n]2cnc(C)c2)C1=O QPIPHGZNRUHSMB-IFQVXRHPSA-N 0.000 description 1
- QPIPHGZNRUHSMB-AHUIGUKZSA-N C[C@H](c1cc(F)cc(F)c1)N(CCC/C1=C\c(cc2)cc(OC)c2-[n]2cnc(C)c2)C1=O Chemical compound C[C@H](c1cc(F)cc(F)c1)N(CCC/C1=C\c(cc2)cc(OC)c2-[n]2cnc(C)c2)C1=O QPIPHGZNRUHSMB-AHUIGUKZSA-N 0.000 description 1
- 0 Cc(nc1)c[n]1-c1c(*)cc(*)cc1 Chemical compound Cc(nc1)c[n]1-c1c(*)cc(*)cc1 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N Cc1c[nH]cn1 Chemical compound Cc1c[nH]cn1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- GIFKVQOPAJDJLO-YQHXDJBWSA-N N'-anilino-N-[(4,5-dimethyl-1,3-thiazol-2-yl)imino]benzenecarboximidamide Chemical compound S1C(C)=C(C)N=C1N=N\C(C=1C=CC=CC=1)=N/NC1=CC=CC=C1 GIFKVQOPAJDJLO-YQHXDJBWSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
試験例1 [ラット胎仔脳由来神経細胞培養におけるAβペプチド定量]
(1)
ラット初代神経細胞培養
胎生18日齢のWistar系ラット(Charles River Japan,Yokohama,Japan)より大脳皮質を単離し培養に供した。具体的には、エーテル麻酔下、妊娠ラットより無菌的に胎仔を摘出した。胎仔より脳を摘出し、氷冷L−15 medium(Invitrogen Corp.Cat #11415−064,Carlsbad,CA USAあるいはSIGMA L1518など)に浸した。その摘出脳から、実体顕微鏡下で大脳皮質を採取した。採取した大脳皮質断片を、0.25% trypsin(Invitrogen Corp.Cat #15050−065,Carlsbad,CA USA)および0.01% DNase(Sigma D5025,St.Louis,MO,USA)を含有した酵素溶液中、37℃下30分間の酵素処理することにより、細胞を分散させた。この際、酵素反応は非働化済みウマ血清を加えることで停止させた。この酵素処理溶液を1500rpmにて5分間遠心分離し、上清を除いた。得られた細胞塊に培地を5〜10ml加えた。培地にはNeurobasal medium(Invitrogen Corp.Cat #21103−049,Carlsbad,CA USA)に、2% B27 supplement(Invitrogen Corp.Cat #17504−044,Carlsbad,CA USA)と25μM 2−mercaptoethanol(2−ME、WAKO Cat #139−06861、Osaka、Japan)と0.5mM L−glutamine(Invitrogen Corp.Cat #25030−081,Carlsbad,CA USA)およびAntibiotics−Antimycotics(Invitrogen Corp.Cat #15240−062,Carlsbad,CA USA)を添加したもの(Neurobasal/B27/2−ME)を用いた。但し、アッセイの際は、2−MEのみを添加しない培地(Neurobasal/B27)を用いた。培地が加えられた細胞塊を、緩やかなピペッティング操作により細胞を再分散させた。この細胞分散液を、40μmナイロンメッシュ(セルストレーナー、Cat #.35−2340、Becton Dickinson Labware、Franklin Lakes,NJ、USA)でろ過し、細胞塊を除くことにより、神経細胞懸濁液を得た。この神経細胞懸濁液を培地にて希釈し、予めpoly−LあるいはD−lysineにてコーティングされた96 well ポリスチレン製培養器(Falcon Cat #.35−3075,Becton Dickinson Labware、Franklin Lakes,NJ,USAを以下の方法でpoly−L−lysineコートを施したもの、あるいはBIOCOATTM cell environments Poly−D−lysine cell ware 96−well plate、Cat #.35−6461、Becton Dickinson Labware、Franklin Lakes,NJ,USA)に初期細胞密度が5 x 105cells/cm2になるように100μl/wellにて播種した。Poly−L−lysineコーティングは以下のように行った。0.15M Borate buffer(pH8.5)を用いて100μg/mlのpoly−L−lysine(SIGMA P2636,St.Louis,MO,USA)溶液を無菌的に調製した。その溶液を100μg/wellにて96wellポリスチレン製培養器に添加し、室温1時間以上、あるいは4℃一晩以上、インキュベートした。その後、コーティングした96wellポリスチレン製培養器は、滅菌水を用いて4回以上洗浄した後、乾燥させるか、あるいは無菌PBSあるいは培地などを用いてすすいだ後に、細胞播種に用いた。播種した細胞は、5% CO2−95% air下、37℃インキュベーター中にて一日培養した後、培地全量を新鮮なNeurobasal/B27/2―ME培地と交換し、引き続き3日間培養した。
化合物添加
培養4日目に薬物添加を以下の通りに行った。培地全量を抜き取り、2−MEを含まない、2% B−27を含有するNeurobasal medium(Neurobasal/B27)を180μl/well加えた。試験化合物のジメチルスルホキシド(以下DMSOと略す)溶液をNeurobasal/B27にて最終濃度の10倍になるように希釈した。この希釈液を20μl/well添加し、よく混和した。最終DMSO濃度は1%以下とした。また対照群にはDMSOのみを添加した。
サンプリング
化合物添加後3日間培養し、培地全量を回収した。得られた培地は、ELISAサンプルとした。Aβx−42測定には希釈せずに、各ELISAに供した。
細胞生存の評価
細胞生存は以下の方法でMTTアッセイにより評価した。培地回収後のwellに温めた培地を100μl/well加え、さらにD−PBS(−)(DULBECCO’S PHOSPHATE BUFFERED SALINE、SIGMA D8537、St.Louis,MO、USA)に溶解した8mg/mlのMTT(SIGMA M2128,St.Louis,MO、USA)溶液を8μl/wellにて添加した。この96wellポリスチレン製培養器を、5%CO2−95%air下、37℃インキュベーター中にて20分間インキュベートした。そこへMTT溶解バッファーを100μl/well加え、5%CO2−95%air下、37℃インキュベーター中にてMTTフォルマザン結晶をよく溶解させた後、各Wellの550nmの吸光度を測定した。MTT溶解バッファーは以下の通りに調製した。N,N’−ジメチルホルムアミド(WAKO 045−02916、Osaka、Japan)と蒸留水を250mLずつ混合した溶液に、100g SDS(ドデシル硫酸ナトリウム(ラウリル硫酸ナトリウム)、WAKO 191−07145、Osaka、Japan)を溶解した。さらに、この溶液に濃塩酸および酢酸を各350μl添加することにより、溶液の最終pHを4.7程度にした。
測定の際、細胞を播種しないwellに培地とMTT溶液のみを加えたものをバックグラウンド(bkg)として設定した。各測定値は、以下の数式に従い、bkgを差し引き、対照群(薬物処理しなかった群、CTRL)に対する比率(% of CTRL)を算出し、細胞生存活性を比較・評価した。
% of CTRL=(A550_sample−A550_bkg)/(A550_CTRL−bkg)x 100
(A550_sample: サンプルwellの550nm吸光度、A550_bkg: バックグラウンドwellの550nm吸光度、A550_CTRL:対照群wellの550 nm吸光度)
Aβ ELISA
Aβ ELISAは、免疫生物研究所(IBL Co.,Ltd.)のHuman Amyloid beta(1−42)Assay Kit(#17711または#27711)を用いた。方法はメーカー推奨のプロトコール(添付文書に記載の方法)にて行った。但しAβ検量線は、beta−amyloid peptide 1−42,rat(Calbiochem.#171596[Aβ42 ])を用いて作製した。結果は、対照群の培地中Aβ濃度に対する百分率(% of CTRL)にて表1に示した。
(2)その結果、本発明化合物は、Aβ42産生低下作用が確認された。
Test Example 1 [Quantification of Aβ peptide in rat fetal brain-derived neuron culture]
(1)
Cerebral cortex was isolated from 18-day-old Wistar rats (Charles River Japan, Yokohama, Japan) of rat primary neuron culture embryos and subjected to culture. Specifically, fetuses were aseptically removed from pregnant rats under ether anesthesia. The brain was removed from the fetus and immersed in ice-cold L-15 medium (Invitrogen Corp. Cat # 11415-064, Carlsbad, CA USA, SIGMA L1518, etc.). Cerebral cortex was collected from the isolated brain under a stereomicroscope. The collected cerebral cortical fragments were converted into an enzyme solution containing 0.25% trypsin (Invitrogen Corp. Cat # 15050-065, Carlsbad, CA USA) and 0.01% DNase (Sigma D5025, St. Louis, MO, USA). The cells were dispersed by treating with an enzyme at 37 ° C. for 30 minutes. At this time, the enzyme reaction was stopped by adding inactivated horse serum. This enzyme-treated solution was centrifuged at 1500 rpm for 5 minutes, and the supernatant was removed. 5 to 10 ml of a medium was added to the obtained cell mass. Neurobasal medium (Invitrogen Corp. Cat # 21103-049, Carlsbad, CA USA) and 2% B27 supplement (Invitrogen Corp. Cat # 17504-044, Carlsbad, CA USA 2-th) , WAKO Cat # 139-06861, Osaka, Japan) and 0.5 mM L-glutamine (Invitrogen Corp. Cat # 25030-081, Carlsbad, CA USA) and Antibiotics-Antiticotics0C CA USA) added ( eurobasal / B27 / 2-ME) was used. However, in the assay, a medium (Neurobasal / B27) to which 2-ME alone was not added was used. The cells were redispersed in the cell mass to which the medium was added by a gentle pipetting operation. This cell dispersion was filtered through a 40 μm nylon mesh (cell strainer, Cat # .35-2340, Becton Dickinson Labware, Franklin Lakes, NJ, USA) to obtain a neuronal cell suspension. . This neuronal cell suspension was diluted with a medium, and a 96-well polystyrene incubator previously coated with poly-L or D-lysine (Falcon Cat # .35-3075, Becton Dickinson Labware, Franklin Lakes, NJ, USA coated with poly-L-lysine by the following method, or BIOCOAT ™ cell environments Poly-D-lysine cell wall 96-well plate, Cat # .35-6461, Becton DickinN Labin, J. USA) was seeded at 100 μl / well so that the initial cell density was 5 × 10 5 cells / cm 2 . Poly-L-lysine coating was performed as follows. A 100 μg / ml poly-L-lysine (SIGMA P2636, St. Louis, MO, USA) solution was aseptically prepared using 0.15 M Borate buffer (pH 8.5). The solution was added to a 96-well polystyrene incubator at 100 μg / well and incubated at room temperature for 1 hour or longer, or at 4 ° C. overnight or longer. Thereafter, the coated 96-well polystyrene incubator was washed four or more times with sterilized water, dried, or rinsed with sterile PBS or a medium, and used for cell seeding. The seeded cells were cultured for one day in a 37 ° C. incubator under 5% CO 2 -95% air, and then the whole medium was replaced with fresh Neurobasal / B27 / 2-ME medium, followed by culturing for 3 days.
Compound addition Drug addition was performed on the 4th day of culture as follows. The whole medium was extracted, and Neurobasal medium (Neurobasal / B27) containing 2% B-27 without 2-ME was added at 180 μl / well. A dimethyl sulfoxide (hereinafter abbreviated as DMSO) solution of the test compound was diluted with Neurobasal / B27 so that the final concentration was 10 times. This diluted solution was added at 20 μl / well and mixed well. The final DMSO concentration was 1% or less. Only DMSO was added to the control group.
After adding the sampling compound, the cells were cultured for 3 days and the whole medium was collected. The obtained culture medium was an ELISA sample. The Aβx-42 measurement was subjected to each ELISA without dilution.
Evaluation of cell survival Cell survival was evaluated by MTT assay by the following method. 100 μl / well of the warmed medium was added to the well after the medium was collected, and further 8 mg / ml MTT dissolved in D-PBS (−) (DULBECCO'S PHOSPHATE BUFFERED SALINE, SIGMA D8537, St. Louis, MO, USA) SIGMA M2128, St. Louis, MO, USA) solution was added at 8 μl / well. This 96-well polystyrene incubator was incubated for 20 minutes in a 37 ° C. incubator under 5% CO 2 -95% air. MTT dissolution buffer was added thereto at 100 μl / well, and MTT formazan crystals were well dissolved in a 37 ° C. incubator under 5% CO 2 -95% air, and then the absorbance at 550 nm of each well was measured. MTT lysis buffer was prepared as follows. 100 g SDS (sodium dodecyl sulfate (sodium lauryl sulfate), WAKO 191-07145, Osaka, Japan) was added to a solution obtained by mixing 250 mL each of N, N′-dimethylformamide (WAKO 045-02916, Osaka, Japan) and distilled water. Dissolved. Further, 350 μl of concentrated hydrochloric acid and acetic acid were added to this solution to bring the final pH of the solution to about 4.7.
At the time of measurement, a background (bkg) obtained by adding only a medium and an MTT solution to a well not seeded with cells was set. For each measured value, bkg was subtracted according to the following formula, a ratio (% of CTRL) to the control group (group not treated with drug, CTRL) was calculated, and cell survival activity was compared and evaluated.
% Of CTRL = (A550_sample−A550_bkg) / (A550_CTRL−bkg) × 100
(A550_sample: 550 nm absorbance of sample well, A550_bkg: 550 nm absorbance of background well, A550_CTRL: 550 nm absorbance of control well)
Aβ ELISA
The Aβ ELISA used Human Amyloid beta (1-42) Assay Kit (# 17711 or # 27711 ) of the Institute for Immunobiology (IBL Co., Ltd.). The method was performed according to the manufacturer's recommended protocol (the method described in the package insert). However, an Aβ calibration curve was prepared using beta-amyloid peptide 1-42, rat ( Calbiochem. # 171596 [Aβ 42 ]) . The results are shown in Table 1 as a percentage (% of CTRL) to the Aβ concentration in the medium of the control group.
(2) As a result, the compound of the present invention was confirmed to have an Aβ42 production lowering effect.
実施例938と同様の方法により、3,5−ジフルオロアセトフェノン(611mg)から表題化合物を含む粗精製物(純度83wt%、738mg)を得た。表題化合物の物性値は以下の通りである。
1H−NMR(CDCl3)δ(ppm):1.48(d,J=6.8Hz,3H),4.19(q,J=6.8Hz,1H),6.72(tt,J=8.4,2.4Hz,1H),6.90(dd,J=8.4Hz,2.4Hz,2H).
1 H-NMR (CDCl 3 ) δ (ppm): 1.48 (d, J = 6.8 Hz, 3H), 4.19 (q, J = 6.8 Hz, 1H), 6.72 (tt, J = 8.4, 2.4 Hz, 1H), 6.90 (dd, J = 8.4 Hz, 2.4 Hz, 2H).
Claims (5)
置換基群A1:(1)水素原子、(2)ハロゲン原子、(3)シアノ基、(4)ニトロ基、(5)C3−8シクロアルキル基、(6)C2−6アルケニル基、(7)C2−6アルキニル基、(8)C1−6アルコキシ基、(9)C3−8シクロアルコキシ基、(10)ホルミル基、(11)C1−6アルキルカルボニル基および(12)C1−6アルキル基(該C1−6アルキル基は、ハロゲン原子、水酸基、シアノ基、C1−6アルコキシ基、C3−8シクロアルキル基およびC1−6アルキルカルボニル基からなる群から選択される1ないし3の置換基で置換されてもよい)。
置換基群A2:(1)水素原子、(2)ハロゲン原子、(3)水酸基、(4)シアノ基、(5)C1−6アルコキシ基(該C1−6アルコキシ基は、ハロゲン原子、シアノ基、C1−6アルコキシ基、C2−6アルケニル基、C2−6アルキニル基およびC3−8シクロアルキル基からなる群から選択される1ないし3の置換基で置換されてもよい)、(6)C3−8シクロアルコキシ基、(7)C2−6アルケニルオキシ基および(8)C2−6アルキニルオキシ基。
置換基群A3:(1)水素原子、(2)ハロゲン原子、(3)置換基群A4から選択される1ないし3の置換基で置換されてもよい5ないし14員芳香族複素環基、(4)C1−6アルキル基(該C1−6アルキル基は、ホルミル基、ハロゲン原子、水酸基、保護基を有する水酸基、シアノ基、C2−6アルケニル基、C2−6アルキニル基、C3−8シクロアルキル基、C1−6アルコキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基、C1−6アルキルスルホニル基、C1−6アルキルカルボニル基、アミノ基(該アミノ基は、1ないし5のハロゲン原子を適宜有するC1−6アルキル基で置換されてもよい)、置換基群A4から選択される1ないし3の置換基で置換されてもよい6ないし14員芳香族炭化水素環基、置換基群A4から選択される1ないし3の置換基で置換さ
れてもよい5ないし14員芳香族複素環基、置換基群A4から選択される1ないし3の置換基で置換されてもよい3ないし14員非芳香族炭化水素環基、置換基群A4から選択される1ないし3の置換基で置換されてもよい5ないし14員非芳香族複素環基および−X−A(ここにおいて、Xは、イミノ基、−O−または−S−を示し、Aは、置換基群A4から選択される1ないし3の置換基で置換されてもよい、6ないし14員芳香族炭化水素環基または5ないし14員芳香族複素環基を示す)からなる群から選択される1ないし3の置換基で置換されてもよい)および(5)C1−6アルコキシ基。
置換基群A4:
(1)水素原子、
(2)ハロゲン原子、
(3)水酸基、
(4)シアノ基、
(5)ニトロ基、
(6)C3−8シクロアルキル基、
(7)C2−6アルケニル基、
(8)C2−6アルキニル基、
(9)C3−8シクロアルコキシ基、
(10)C3−8シクロアルキルチオ基、
(11)ホルミル基、
(12)C1−6アルキルカルボニル基、
(13)C1−6アルキルチオ基、
(14)C1−6アルキルスルフィニル基、
(15)C1−6アルキルスルホニル基、
(16)ヒドロキシイミノ基、
(17)C1−6アルコキシイミノ基、
(18)C1−6アルキル基(該C1−6アルキル基は、下記置換基群より選択される1ないし3の置換基を有していてもよい)
(a)ハロゲン原子、
(b)水酸基、
(c)シアノ基、
(d)C3−8シクロアルキル基、
(e)C1−6アルキルチオ基、
(f)C1−6アルキルスルフィニル基、
(g)C1−6アルキルスルホニル基、
(h)C1−6アルキルカルボニル基、
(i)ヒドロキシイミノ基、
(j)C1−6アルコキシイミノ基、
(k)C1−6アルコキシ基(該C1−6アルコキシ基は、水酸基で置換されてもよい。)、
(l)カルバモイル基(該カルバモイル基は、C1−6アルキル基、C2−6アルケニル基およびC2−6アルキニル基からなる群より選択される1ないし2の置換基で置換されてもよい。)、
(m)6ないし14員芳香族炭化水素環基(該6ないし14員芳香族炭化水素環基は下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい)、
(n)3ないし14員非芳香族炭化水素環基(該3ないし14員非芳香族炭化水素環基は、下記置換基群A4−1より選択される置換基を1ないし3の置換基で置換されてもよい。)、
(o)5ないし14員芳香族複素環基(該5ないし14員芳香族複素環基は、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい。)
(p)5ないし14員非芳香族複素環基(該5ないし14員非芳香族複素環基は、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい。)および
(q)−X−A(ここにおいて、Xは、イミノ基、−O−または−S−を示し、Aは、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい、6ないし14員芳香族炭化水素環基または5ないし14員芳香族複素環基を示す。)、
(19)C1−6アルコキシ基、
(20)アミノ基(該アミノ基は、6ないし14員芳香族炭化水素環基で置換されてもよいC1−6アルキル基、C2−6アルケニル基およびC2−6アルキニル基からなる群より選択される1ないし2の置換基で置換されてもよい。)
(21)カルバモイル基(該カルバモイル基は、C1−6アルキル基、C2−6アルケニル基およびC2−6アルキニル基からなる群より選択される1ないし2の置換基で置換されてもよい。)、
(22)6ないし14員芳香族炭化水素環基(該6ないし14員芳香族炭化水素環基は、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい。)、
(23)5ないし14員芳香族複素環基(該5ないし14員芳香族複素環基は、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい。)、
(24)3ないし14員非芳香族炭化水素環基(該3ないし14員非芳香族炭化水素環基は、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい。)、
(25)5ないし14員非芳香族複素環基(該5ないし14員非芳香族複素環基は、下記置換基群A4−1より選択される1ないし3の置換基で置換されてもよい。)、
(26)C2−6アルケニルオキシ基、
(27)C2−6アルキニルオキシ基、
(28)C3−8シクロアルキルスルフィニル基、
(29)C3−8シクロアルキルスルホニル基、
(30)−X−A(ここにおいて、Xは、イミノ基、−O−または−S−を示し、Aは、下記置換基群A4−1から選択される1ないし3の置換基で置換されてもよい、6ないし14員芳香族炭化水素環基または5ないし14員芳香族複素環基を示す)、
(31)−CO−A(ここにおいて、Aは、前記の意味を有する)および
(32)=CH―A(ここにおいて、Aは、前記の意味を有する)。
置換基群A4−1:
(1)ハロゲン原子、
(2)水酸基、
(3)シアノ基、
(4)ニトロ基、
(5)C1−6アルキルカルボニル基、
(6)C1−6アルキルチオ基、
(7)C1−6アルキルスルフィニル基、
(8)C1−6アルキルスルホニル基、
(9)C1−6アルコキシ基(該C1−6アルコキシ基は、水酸基およびハロゲン原子からなる群より選択される1ないし3の置換基で置換されてもよい。)、
(10)C2−6アルケニルオキシ基、
(11)C2−6アルキニルオキシ基、
(12)C1−6アルキル基(該C1−6アルキル基は、下記置換基群より選択される1ないし3の置換基を有していてもよい。)
(i)ハロゲン原子、
(ii)水酸基、
(iii)C1−6アルコキシ基(該C1−6アルコキシ基は、C3−8シクロアルキル基で置換されてもよい。)、
(iv)C2−6アルケニルオキシ基、
(v)C2−6アルキニルオキシ基、
(vi)C1−6アルキルチオ基、
(vii)C1−6アルキルスルフィニル基、
(viii)C1−6アルキルスルホニル基、
(ix)6ないし14員芳香族炭化水素環基(該6ないし14員芳香族炭化水素環基は、ハロゲン原子、1ないし3のハロゲン原子で置換されてもよいC1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、1ないし3のハロゲン原子で置換されてもよいC1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基を有していてもよい。)、
(x)3ないし14員非芳香族炭化水素環基(該3ないし14員非芳香族炭化水素環基は、ハロゲン原子、1ないし3のハロゲン原子で置換されてもよいC1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、1ないし3のハロゲン原子で置換されてもよいC1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基を有していてもよい。)、
(xi)5ないし14員芳香族複素環基(該5ないし14員芳香族複素環基は、ハロゲン原子、1ないし3のハロゲン原子で置換されてもよいC1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、1ないし3のハロゲン原子で置換されてもよいC1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基を有していてもよい。)および
(xii)5ないし14員非芳香族複素環基(該5ないし14員非芳香族複素環基は、ハロゲン原子、1ないし3のハロゲン原子で置換されてもよいC1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、1ないし3のハロゲン原子で置換されてもよいC1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基を有していてもよい。)、
(13)アミノ基(該アミノ基は、C1−6アルキル基、C2−6アルケニル基およびC2−6アルキニル基からなる群より選択される1ないし2の置換基で置換されてもよい。
)、
(14)6ないし14員芳香族炭化水素環基(該6ないし14員芳香族炭化水素環基は、ハロゲン原子、C1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、C1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基で置換されてもよい。)、
(15)3ないし14員非芳香族炭化水素環基(該3ないし14員非芳香族炭化水素環基は、ハロゲン原子、C1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、C1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基で置換されてもよい。)、
(16)5ないし14員芳香族複素環基(該5ないし14員芳香族複素環基は、ハロゲン原子、水酸基、1ないし3の水酸基で置換されてもよいC1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、1ないし3のハロゲン原子で置換されてもよいC1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基で置換されてもよい。)、
(17)5ないし14員非芳香族複素環基(該5ないし14員非芳香族複素環基は、ハロゲン原子、C1−6アルキル基、C2−6アルケニル基、C2−6アルキニル基、C1−6アルコキシ基、C2−6アルケニルオキシ基、C2−6アルキニルオキシ基、C1−6アルキルチオ基、C1−6アルキルスルフィニル基およびC1−6アルキルスルホニル基からなる群より選択される1ないし3の置換基で置換されてもよい。)、
(18)−X−A(ここにおいて、Xは、イミノ基、−O−または−S−を示し、Aは、1ないし3のハロゲン原子で置換されてもよい、6ないし14員芳香族炭化水素環基または5ないし14員芳香族複素環基を示す。)および
(19)−CO−A(ここにおいて、Aは1ないし3のハロゲン原子で置換されてもよい、6ないし14員芳香族炭化水素環基または5ないし14員芳香族複素環基を示す。 Following formula (5a)
Substituent group A1: (1) hydrogen atom, (2) halogen atom, (3) cyano group, (4) nitro group, (5) C3-8 cycloalkyl group, (6) C2-6 alkenyl group, (7 ) C2-6 alkynyl group, (8) C1-6 alkoxy group, (9) C3-8 cycloalkoxy group, (10) formyl group, (11) C1-6 alkylcarbonyl group and (12) C1-6 alkyl group (The C1-6 alkyl group is a 1 to 3 substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-6 alkoxy group, a C3-8 cycloalkyl group and a C1-6 alkylcarbonyl group. May be substituted).
Substituent group A2: (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) cyano group, (5) C1-6 alkoxy group (the C1-6 alkoxy group is a halogen atom, cyano group) , A C1-6 alkoxy group, a C2-6 alkenyl group, a C2-6 alkynyl group and a C3-8 cycloalkyl group, which may be substituted with 1 to 3 substituents), (6) C3 -8 cycloalkoxy group, (7) C2-6 alkenyloxy group and (8) C2-6 alkynyloxy group.
Substituent group A3: (1) a hydrogen atom, (2) a halogen atom, (3) a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group A4, (4) C1-6 alkyl group (the C1-6 alkyl group is a formyl group, a halogen atom, a hydroxyl group, a hydroxyl group having a protecting group, a cyano group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-8 cyclohexane). An alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, a C1-6 alkylsulfinyl group, a C1-6 alkylsulfonyl group, a C1-6 alkylcarbonyl group, an amino group (the amino group is 1 to 5 halogen atoms) And a 6 to 14-membered aromatic hydrocarbon ring group that may be substituted with 1 to 3 substituents selected from Substituent Group A4 5- to 14-membered aromatic heterocyclic group which may be substituted with 1 to 3 substituents selected from Substituent Group A4, and 1 to 3 substituents selected from Substituent Group A4 A 3- to 14-membered non-aromatic hydrocarbon ring group, a 5- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from Substituent Group A4, and , X represents an imino group, —O— or —S—, and A represents a 6 to 14 membered aromatic hydrocarbon ring which may be substituted with 1 to 3 substituents selected from the substituent group A4 A 1 to 3 substituents selected from the group consisting of a group or a 5- to 14-membered aromatic heterocyclic group) and (5) a C1-6 alkoxy group.
Substituent group A4:
(1) a hydrogen atom,
(2) a halogen atom,
(3) hydroxyl group,
(4) a cyano group,
(5) Nitro group,
(6) a C3-8 cycloalkyl group,
(7) a C2-6 alkenyl group,
(8) a C2-6 alkynyl group,
(9) a C3-8 cycloalkoxy group,
(10) a C3-8 cycloalkylthio group,
(11) formyl group,
(12) a C1-6 alkylcarbonyl group,
(13) a C1-6 alkylthio group,
(14) a C1-6 alkylsulfinyl group,
(15) a C1-6 alkylsulfonyl group,
(16) hydroxyimino group,
(17) a C1-6 alkoxyimino group,
(18) C1-6 alkyl group (the C1-6 alkyl group may have 1 to 3 substituents selected from the following substituent group)
(A) a halogen atom,
(B) a hydroxyl group,
(C) a cyano group,
(D) a C3-8 cycloalkyl group,
(E) a C1-6 alkylthio group,
(F) a C1-6 alkylsulfinyl group,
(G) a C1-6 alkylsulfonyl group,
(H) a C1-6 alkylcarbonyl group,
(I) a hydroxyimino group,
(J) a C1-6 alkoxyimino group,
(K) a C1-6 alkoxy group (the C1-6 alkoxy group may be substituted with a hydroxyl group),
(L) a carbamoyl group (the carbamoyl group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, a C2-6 alkenyl group, and a C2-6 alkynyl group);
(M) a 6 to 14-membered aromatic hydrocarbon ring group (the 6 to 14-membered aromatic hydrocarbon ring group may be substituted with 1 to 3 substituents selected from the following substituent group A4-1) ,
(N) a 3- to 14-membered non-aromatic hydrocarbon ring group (the 3- to 14-membered non-aromatic hydrocarbon ring group is a substituent selected from the following substituent group A4-1 with 1 to 3 substituents; May be substituted).
(O) 5- to 14-membered aromatic heterocyclic group (The 5- to 14-membered aromatic heterocyclic group may be substituted with 1 to 3 substituents selected from the following substituent group A4-1)
(P) a 5- to 14-membered non-aromatic heterocyclic group (the 5- to 14-membered non-aromatic heterocyclic group may be substituted with 1 to 3 substituents selected from the following substituent group A4-1) And (q) -XA (wherein X represents an imino group, -O- or -S-, and A represents 1 to 3 substituents selected from the following substituent group A4-1) A 6 to 14-membered aromatic hydrocarbon ring group or a 5 to 14-membered aromatic heterocyclic group which may be substituted with
(19) a C1-6 alkoxy group,
(20) an amino group (the amino group is selected from the group consisting of a C1-6 alkyl group, a C2-6 alkenyl group and a C2-6 alkynyl group which may be substituted with a 6 to 14-membered aromatic hydrocarbon ring group) 1 to 2 substituents may be substituted.)
(21) a carbamoyl group (the carbamoyl group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, a C2-6 alkenyl group, and a C2-6 alkynyl group);
(22) 6 to 14-membered aromatic hydrocarbon ring group (the 6 to 14-membered aromatic hydrocarbon ring group may be substituted with 1 to 3 substituents selected from the following substituent group A4-1) ),
(23) 5- to 14-membered aromatic heterocyclic group (The 5- to 14-membered aromatic heterocyclic group may be substituted with 1 to 3 substituents selected from the following substituent group A4-1) ,
(24) 3- to 14-membered non-aromatic hydrocarbon ring group (the 3- to 14-membered non-aromatic hydrocarbon ring group is substituted with 1 to 3 substituents selected from the following substituent group A4-1) May be good),
(25) 5- to 14-membered non-aromatic heterocyclic group (The 5- to 14-membered non-aromatic heterocyclic group may be substituted with 1 to 3 substituents selected from the following substituent group A4-1) ),
(26) a C2-6 alkenyloxy group,
(27) a C2-6 alkynyloxy group,
(28) a C3-8 cycloalkylsulfinyl group,
(29) a C3-8 cycloalkylsulfonyl group,
(30) —X—A (wherein X represents an imino group, —O— or —S—, and A is substituted with 1 to 3 substituents selected from the following substituent group A4-1) Which may be a 6 to 14-membered aromatic hydrocarbon ring group or a 5 to 14-membered aromatic heterocyclic group),
(31) -CO-A (where A has the above meaning) and (32) = CH-A (where A has the above meaning).
Substituent group A4-1:
(1) a halogen atom,
(2) hydroxyl group,
(3) a cyano group,
(4) Nitro group,
(5) a C1-6 alkylcarbonyl group,
(6) C1-6 alkylthio group,
(7) C1-6 alkylsulfinyl group,
(8) C1-6 alkylsulfonyl group,
(9) C1-6 alkoxy group (the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and a halogen atom);
(10) a C2-6 alkenyloxy group,
(11) a C2-6 alkynyloxy group,
(12) C1-6 alkyl group (The C1-6 alkyl group may have 1 to 3 substituents selected from the following substituent group)
(I) a halogen atom,
(Ii) a hydroxyl group,
(Iii) C1-6 alkoxy group (the C1-6 alkoxy group may be substituted with a C3-8 cycloalkyl group),
(Iv) a C2-6 alkenyloxy group,
(V) a C2-6 alkynyloxy group,
(Vi) a C1-6 alkylthio group,
(Vii) a C1-6 alkylsulfinyl group,
(Viii) a C1-6 alkylsulfonyl group,
(Ix) a 6 to 14-membered aromatic hydrocarbon ring group (the 6 to 14-membered aromatic hydrocarbon ring group is a C1-6 alkyl group which may be substituted with a halogen atom or 1 to 3 halogen atoms; 6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group optionally substituted with 1 to 3 halogen atoms, C2-6 alkenyloxy group, C2-6 alkynyloxy group, C1-6 alkylthio group, C1- 1 to 3 substituents selected from the group consisting of a 6 alkylsulfinyl group and a C1-6 alkylsulfonyl group).
(X) a 3- to 14-membered non-aromatic hydrocarbon ring group (the 3- to 14-membered non-aromatic hydrocarbon ring group is a C1-6 alkyl group which may be substituted with a halogen atom, 1 to 3 halogen atoms, A C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group optionally substituted with 1 to 3 halogen atoms, a C2-6 alkenyloxy group, a C2-6 alkynyloxy group, a C1-6 alkylthio group, Optionally having 1 to 3 substituents selected from the group consisting of a C1-6 alkylsulfinyl group and a C1-6 alkylsulfonyl group).
(Xi) a 5- to 14-membered aromatic heterocyclic group (the 5- to 14-membered aromatic heterocyclic group is a C1-6 alkyl group or C2-6 alkenyl optionally substituted with 1 to 3 halogen atoms) Group, C2-6 alkynyl group, C1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms, C2-6 alkenyloxy group, C2-6 alkynyloxy group, C1-6 alkylthio group, C1-6 alkyl 1 to 3 substituents selected from the group consisting of a sulfinyl group and a C 1-6 alkylsulfonyl group.) And (xii) a 5 to 14-membered non-aromatic heterocyclic group (the 5 to 14 The member non-aromatic heterocyclic group is a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group which may be substituted with 1 to 3 halogen atoms. C1-6 alkoxy group, C2-6 alkenyloxy group, C2-6 alkynyloxy group, C1-6 alkylthio group, C1-6 alkylsulfinyl group and C1-6 alkyl which may be substituted with 1 to 3 halogen atoms Optionally having 1 to 3 substituents selected from the group consisting of sulfonyl groups).
(13) Amino group (The amino group may be substituted with 1 to 2 substituents selected from the group consisting of a C1-6 alkyl group, a C2-6 alkenyl group, and a C2-6 alkynyl group.
),
(14) a 6 to 14-membered aromatic hydrocarbon ring group (the 6 to 14-membered aromatic hydrocarbon ring group includes a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1- 1 to 3 substituents selected from the group consisting of 6 alkoxy groups, C2-6 alkenyloxy groups, C2-6 alkynyloxy groups, C1-6 alkylthio groups, C1-6 alkylsulfinyl groups, and C1-6 alkylsulfonyl groups May be substituted with
(15) 3- to 14-membered non-aromatic hydrocarbon ring group (the 3- to 14-membered non-aromatic hydrocarbon ring group includes a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, 1 to 3 selected from the group consisting of a C1-6 alkoxy group, a C2-6 alkenyloxy group, a C2-6 alkynyloxy group, a C1-6 alkylthio group, a C1-6 alkylsulfinyl group and a C1-6 alkylsulfonyl group May be substituted with a substituent),
(16) 5- to 14-membered aromatic heterocyclic group (the 5- to 14-membered aromatic heterocyclic group is a C1-6 alkyl group optionally substituted with a halogen atom, a hydroxyl group, or 1 to 3 hydroxyl groups, C2-6 An alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group optionally substituted with 1 to 3 halogen atoms, a C2-6 alkenyloxy group, a C2-6 alkynyloxy group, a C1-6 alkylthio group, C1-6 1 to 3 substituents selected from the group consisting of an alkylsulfinyl group and a C1-6 alkylsulfonyl group may be substituted).
(17) 5- to 14-membered non-aromatic heterocyclic group (the 5- to 14-membered non-aromatic heterocyclic group includes a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, C1- 1 to 3 substituents selected from the group consisting of 6 alkoxy groups, C2-6 alkenyloxy groups, C2-6 alkynyloxy groups, C1-6 alkylthio groups, C1-6 alkylsulfinyl groups, and C1-6 alkylsulfonyl groups May be substituted with
(18) —X—A (wherein X represents an imino group, —O— or —S—, and A represents a 6 to 14 membered aromatic carbon atom optionally substituted with 1 to 3 halogen atoms) A hydrogen ring group or a 5- to 14-membered aromatic heterocyclic group) and (19) -CO-A (wherein A is a 6- to 14-membered aromatic group optionally substituted by 1 to 3 halogen atoms) A hydrocarbon ring group or a 5- to 14-membered aromatic heterocyclic group is shown.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007306088A JP4827821B2 (en) | 2004-05-26 | 2007-11-27 | Cinnamide compounds |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004155790 | 2004-05-26 | ||
JP2004155790 | 2004-05-26 | ||
JP2004310909 | 2004-10-26 | ||
JP2004310909 | 2004-10-26 | ||
JP2007306088A JP4827821B2 (en) | 2004-05-26 | 2007-11-27 | Cinnamide compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006513906A Division JP4101852B2 (en) | 2004-05-26 | 2005-05-25 | Cinnamide compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008101015A JP2008101015A (en) | 2008-05-01 |
JP2008101015A5 true JP2008101015A5 (en) | 2009-05-07 |
JP4827821B2 JP4827821B2 (en) | 2011-11-30 |
Family
ID=39435609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007306088A Expired - Fee Related JP4827821B2 (en) | 2004-05-26 | 2007-11-27 | Cinnamide compounds |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4827821B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012184169A (en) * | 2011-03-03 | 2012-09-27 | Dainippon Printing Co Ltd | Method for producing base-generating agent |
AU2013202978B2 (en) * | 2012-01-25 | 2016-05-19 | Novartis Ag | Heterocyclic compounds and methods for their use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4508718A (en) * | 1984-01-16 | 1985-04-02 | Warner-Lambert Company | Cardiotonic and antihypertensive oxadiazinone compounds |
-
2007
- 2007-11-27 JP JP2007306088A patent/JP4827821B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Parekh et al. | Synthesis and antibacterial activity of some Schiff bases derived from 4-aminobenzoic acid | |
CN102711468B (en) | Pyrido[4,3-B]indoles and methods of use | |
Plech et al. | Search for factors affecting antibacterial activity and toxicity of 1, 2, 4-triazole-ciprofloxacin hybrids | |
CN101316853B (en) | Oxazolopyridine derivatives as SIRTUIN modulators | |
EP1945209A2 (en) | Broad spectrum antibacterial compounds | |
Bodo et al. | Effects of sub-toxic cadmium concentrations on bone gene expression program: results of an in vitro study | |
JP2011507910A (en) | Methods for changing the lifetime of eukaryotes | |
Zhao et al. | Biological evaluation of halogenated thiazolo [3, 2-a] pyrimidin-3-one carboxylic acid derivatives targeting the YycG histidine kinase | |
Garcia et al. | Modeling the dynamic AMD-associated chronic oxidative stress changes in human ESC and iPSC-derived RPE cells | |
CN102711466A (en) | Bridged heterocyclic compounds and methods of use | |
CN102480955A (en) | Pyrido [4,3-b] indoles and methods of use | |
JP2008101015A5 (en) | ||
Münch et al. | Propagation of the prion phenomenon: beyond the seeding principle | |
Adamec et al. | Hybrid molecules of estrone: New compounds with potential antibacterial, antifungal, and antiproliferative activities | |
Delgado-Calle et al. | Nitric oxide is involved in the down-regulation of SOST expression induced by mechanical loading | |
Kiran et al. | Design, synthesis, and biological activity of new bis-1, 2, 3-triazole derivatives bearing thiophene-chalcone moiety | |
Zhao et al. | MiR-137-3p exacerbates the ischemia-reperfusion injured cardiomyocyte apoptosis by targeting KLF15 | |
WO2012006276A1 (en) | Inhibition of bacterial biofilms with aryl carbamates | |
Katti et al. | Marf-mediated mitochondrial fusion is imperative for the development and functioning of indirect flight muscles (IFMs) in drosophila | |
JP2011513409A (en) | Hexahydrocyclopentyl [f] indazolesulfonamides and their derivatives as selective glucocorticoid receptor modulators | |
Mohite et al. | Synthesis and antifungal activity of 3-aryl-1-(5-phenyl-1H-tetrazol-1-yl) prop-2-en-1-One | |
JP2012513972A (en) | Novel oxime derivative of 3,5-seco-4-nor-cholestane, pharmaceutical composition containing the same, and preparation method thereof | |
Unnissa et al. | Synthesis and in vitro anti microbial evaluation including anti-malarial activity of pyrazole based novel cinnoline derivatives | |
JP7245911B2 (en) | Process route, crystal form and method for preparing the compound of formula (IV) | |
Jamkhandi et al. | Synthesis and Antimicrobial Evaluation of 1H-Benzotriazol-1-yl {2-hydroxy-5-[(E) phenyldiazenyl] phenyl} methanone derivative |